INT325244

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.80
First Reported 2010
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 1
Total Number 14
Disease Relevance 4.17
Pain Relevance 1.80

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Il33) extracellular region (Il33) nucleus (Il33)
Anatomy Link Frequency
mast cells 6
basophils 1
Il33 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 406 99.90 Very High Very High Very High
cytokine 238 98.28 Very High Very High Very High
Inflammatory response 70 96.76 Very High Very High Very High
Inflammatory stimuli 14 15.12 Low Low
fibrosis 14 5.00 Very Low Very Low Very Low
Pain 14 5.00 Very Low Very Low Very Low
Inflammatory mediators 14 5.00 Very Low Very Low Very Low
chemokine 14 5.00 Very Low Very Low Very Low
antagonist 14 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
INFLAMMATION 490 99.90 Very High Very High Very High
Necrosis 14 99.62 Very High Very High Very High
Anaphylaxis 308 98.04 Very High Very High Very High
Sprains And Strains 42 82.96 Quite High
Rhinitis 14 40.24 Quite Low
Disease 70 5.00 Very Low Very Low Very Low
Pressure And Volume Under Development 42 5.00 Very Low Very Low Very Low
Asthma 28 5.00 Very Low Very Low Very Low
Increased Venous Pressure Under Development 28 5.00 Very Low Very Low Very Low
Hypersensitivity 28 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The mechanisms controlling release of IL-33 are unclear at this time.
Localization (release) of IL-33
1) Confidence 0.80 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0.23 Pain Relevance 0.16
Currently, only induction of necrosis has been shown to secrete IL-33 [7], leading to the proposal that IL-33 functions as an alarmin [48].
Localization (secrete) of IL-33 associated with necrosis
2) Confidence 0.80 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0.36 Pain Relevance 0.14
One caveat to our in vitro studies using BMMC is that we have failed to detect secretion of IL-33 into the supernatants.
Localization (secretion) of IL-33
3) Confidence 0.80 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0.18 Pain Relevance 0.17
However, while our data failed to detect IL-33 release from mast cells in vitro, our passive cutaneous anaphylaxis experiments demonstrates a functional role for IL-33 and ST2 during in vivo inflammation.
Localization (release) of IL-33 in mast cells associated with inflammation and anaphylaxis
4) Confidence 0.80 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0.34 Pain Relevance 0.12
Similar cell-to-cell interactions might also be needed for mast cells to release IL-33.
Localization (release) of IL-33 in mast cells
5) Confidence 0.80 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0.56 Pain Relevance 0.11
One possibility is that additional signals might be required for the secretion of IL-33 from mast cells.
Localization (secretion) of IL-33 in mast cells
6) Confidence 0.80 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0.33 Pain Relevance 0.09
secretion [36], was insufficient to induce secretion of IL-33 (data not shown), supporting the lack of a caspase-1 mediated release mechanism for IL-33, while LPS (5–100 ng/ml), shown to promote release of IL-6 and TNF?
Localization (secretion) of IL-33
7) Confidence 0.80 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0 Pain Relevance 0.03
However, they also failed to detect any IL-33 in cell supernatants, suggesting that release of IL-33 is more complicated than a simple secretion process.
Localization (release) of IL-33
8) Confidence 0.80 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0.35 Pain Relevance 0.16
As such, BMMC may be functionally refractory to release of IL-33.
Localization (release) of IL-33
9) Confidence 0.80 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0.23 Pain Relevance 0.15
We postulated that released IL-33 might promote its own expression by activating mast cells, in a potentially autocrine fashion.
Localization (released) of IL-33 in mast cells
10) Confidence 0.74 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0 Pain Relevance 0.09
However, fetal skin-derived mast cells, which express a more diverse range of Toll-like receptors [47], also failed to release IL-33 (data not shown).
Neg (failed) Localization (release) of IL-33 in mast cells
11) Confidence 0.74 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0.23 Pain Relevance 0.16
Therefore, mast cells could trigger the recruitment of late-phase inflammation via IL-33-mediated recruitment of ST2-expressing basophils to the site of antigen exposure.
Localization (recruitment) of IL-33-mediated in basophils associated with inflammation
12) Confidence 0.74 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0.45 Pain Relevance 0.15
However, they also failed to detect any IL-33 in cell supernatants, suggesting that release of IL-33 is more complicated than a simple secretion process.
Neg (failed) Localization (detect) of IL-33
13) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0.34 Pain Relevance 0.16
Whether IL-33 associated production and release processes are unique to mast cells or shared by other IL-33 expressing cells remains to be determined.
Localization (release) of IL-33 in mast cells
14) Confidence 0.61 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0.58 Pain Relevance 0.11

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox